Antimicrobial Stewardship Program 2025 – 400 Free Practice Questions to Pass the Exam

Carbapenem Resistant Enterobacteriaceae (CRE) is well-known for its significant resistance profile, particularly its resistance to carbapenems, which are usually considered last-line antibiotics for treating severe infections caused by Enterobacteriaceae. The notable characteristic of these organisms lies in their ability to resist not only carbapenems but often many other beta-lactam antibiotics as well. This extensive resistance makes the treatment of infections caused by CRE very challenging for healthcare providers.

Resistance in CRE often stems from the production of specific enzymes such as carbapenemases, which break down beta-lactam antibiotics, rendering them ineffective. While some CRE strains may exhibit variable susceptibility to certain beta-lactams, the general classification of CRE indicates a high level of resistance in most cases, which aligns with the correct answer.

Understanding the resistance mechanisms and how they affect treatment options is crucial for antimicrobial stewardship, as it informs decisions about antibiotic selection and the implementation of effective infection control measures.